 Glucagon-Like Peptide 1
"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
| Descriptor ID |
D052216
|
| MeSH Number(s) |
D06.472.317.469.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in this website by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2008 | 1 | 1 | 2 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 1 | 3 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 0 | 2 | | 2013 | 3 | 3 | 6 | | 2014 | 5 | 2 | 7 | | 2015 | 2 | 3 | 5 | | 2016 | 1 | 2 | 3 | | 2017 | 3 | 1 | 4 | | 2018 | 1 | 0 | 1 | | 2019 | 3 | 4 | 7 | | 2020 | 4 | 0 | 4 | | 2021 | 1 | 1 | 2 | | 2022 | 1 | 3 | 4 | | 2023 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Park J, Ntelis S, Yunasan E, Downton KD, Yip TC, Munir KM, Haq N. Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2023 Dec 21; 109(1):279-292.
-
Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity Management in Adults: A Review. JAMA. 2023 11 28; 330(20):2000-2015.
-
Perreault L, Bergman BC. Out of stock: A brief clinical reference for rough equivalency of glucagon-like peptide-1 (GLP-1) ? glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes. J Diabetes. 2024 Jun; 16(6):e13505.
-
Salahuddin T, Hebbe A, Daus M, Essien UR, Waldo SW, Rodriguez F, Ho PM, Simons C, Gilmartin HM, Doll JA. Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021. Am Heart J. 2024 02; 268:68-79.
-
Dumolt JH, Rosario FJ, Kramer AC, Horwitz S, Powell TL, Jansson T. Maternal glucagon-like peptide-1 is positively associated with fetal growth in pregnancies complicated with obesity. Clin Sci (Lond). 2023 04 26; 137(8):663-678.
-
Tell SS, Schafer M, Vigers T, Baumgartner AD, Lyon E, Gross S, Polsky S, Snell-Bergeon JK, Schauer IE, Nadeau KJ. Bromocriptine quick-release as adjunct therapy in youth and adults with type 1 diabetes: A randomized, placebo-controlled crossover study. Diabetes Obes Metab. 2022 11; 24(11):2148-2158.
-
Kim KS, Peck BC, Hung YH, Koch-Laskowski K, Wood L, Dedhia PH, Spence JR, Seeley RJ, Sethupathy P, Sandoval DA. Vertical sleeve gastrectomy induces enteroendocrine cell differentiation of intestinal stem cells through bile acid signaling. JCI Insight. 2022 06 08; 7(11).
-
Tommerdahl KL, Kendrick J, Bjornstad P. The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial. Clin J Am Soc Nephrol. 2022 06; 17(6):905-907.
-
Al Rifai M, Vaughan EM, Abushamat LA, Lee M, Ramsey DJ, Gupta K, Navaneethan SD, Virani SS. Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.
-
Evers SS, Shao Y, Ramakrishnan SK, Shin JH, Bozadjieva-Kramer N, Irmler M, Stemmer K, Sandoval DA, Shah YM, Seeley RJ. Gut HIF2a signaling is increased after VSG, and gut activation of HIF2a decreases weight, improves glucose, and increases GLP-1 secretion. Cell Rep. 2022 01 18; 38(3):110270.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|